Navigation Links
Actavis Launches Generic Equivalent of Ritalin LA® in the US, With 180-Day Exclusivity
Date:1/4/2012

MORRISTOWN, N.J., Jan. 4, 2012 /PRNewswire/ -- Actavis Group, an international generic pharmaceuticals company, today announced that it recently received approval from the US Food & Drug Administration to market Methylphenidate Hydrochloride Extended-Release Capsules (LA) CII, USP, 20mg, 30mg, and 40mg.  Actavis has first-to-file exclusivity on the 20mg, 30mg, and 40mg strengths. Distribution of the product has commenced. 

Methylphenidate Hydrochloride Extended-Release Capsules 20mg, 30mg and 40mg, the generic equivalent of Ritalin LA® 20mg, 30mg, and 40mg, had US sales of approximately $80.7 million for the 12 months ending September 30, 2011, according to IMS Health.   

Commenting on the new approval, Doug Boothe, CEO of Actavis in the US, said:

"The approval and launch of Methylphenidate Hydrochloride Extended-Release Capsules (LA) offers a significant value to our customers and patients.  This approval, along with the first-to-file exclusivity, also underscores Actavis' emphasis and commitment to bringing complex controlled-release products to the marketplace."

Please see prescribing information at www.actavis.us/methylphenidate.

About Actavis:

Actavis Inc. is the U.S. subsidiary of Actavis Group hf. Approximately one third of Actavis' sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis Inc. has U.S. manufacturing and packaging facilities in Elizabeth, NJ; a manufacturing facility in Lincolnton, NC; and research and development facilities in Owings Mills, MD and Sunrise, FL. Please visit www.actavis.us for more information.

Ritalin LA® is a registered trademark of a party other than Actavis.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis.  By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.


'/>"/>
SOURCE Actavis
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis First-To-Market with Generic Equivalents of Clobex® Shampoo and Clobex® Topical Lotion
2. Actavis to Launch Novel Pain Medication in the US
3. QRxPharma Announces Strategic Partnership with Actavis
4. Actavis Launches Generic KADIAN® Capsules in the U.S.
5. Actavis Plans Latin America Expansion
6. Actavis Launches Generic Keppra XR® Tablets in the U.S.
7. Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
8. Actavis Launches Oxymorphone Hydrochloride Extended-Release Tablets, CII in the U.S.
9. Actavis Hails U.S. Supreme Court Decision in Labeling Cases
10. Actavis Receives FDA Approval of Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV in the U.S.
11. Actavis Receives FDA Approval of Donepezil Hydrochloride Tablets in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... COTTAGE, New York , January 13, 2017 ... and rising prevalence of AIDS will collectively contribute to the ...  is expected to reach a value of US$ 551.0 Mn ... will remain the most lucrative markets for western ... to lead the market globally. ...
(Date:1/13/2017)... Jan. 13, 2017 Wichita Laser Clinic ... laser treatments to Wichita, Kansas ... advanced treatments for skin rejuvenation, getting rid of unwanted ... and vascular lesions. "Since being in the ... Wichita for laser tattoo removal ...
(Date:1/13/2017)... -- The 2016 election resulted in a big ... in favor of legalizing cannabis for recreational use, including ... U.S. In addition, the state of Colorado ... sales. The ArcView Group has published an updated research report ... in the U.S. last year reached $6.7 billion, a growth of ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... Atlanta-based incentive company ... innovator in the wheelchair accessibility industry, BraunAbility . Incentive Solutions will provide ... wheelchair accessible vehicles. With this new incentive plan, BraunAbility plans to continue their ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... teacher, http://www.ageofautism.com/legal , Sharon Kleyne, America’s leading water educator, researcher and ... nationally syndicated radio program, The Sharon Kleyne Hour Power of Water, Global Climate ...
(Date:1/16/2017)... ... 16, 2017 , ... In 1985, the International Association of ... to an international multidisciplinary group of healthcare treatment providers and helping professions who ... its mission at the grassroots level, iaedp launched MemberSHARE, an online peer community ...
(Date:1/16/2017)... ... ... San Francisco dentist, Dr. Ben Amini , the founder at CitiDent, ... capable of taking digital impressions of teeth and gums. Conventional bite impressions have lagged ... , in terms of speed, efficiency and patient comfort. Increasingly, digital impressions are being ...
(Date:1/16/2017)... ... January 16, 2017 , ... NexTec Group has been selected ... 100 organizations honored for their accomplishments in the field of midmarket financial software. , ... and recognition, and innovation. Selection is not based on revenue and those firms chosen ...
Breaking Medicine News(10 mins):